Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN: Abetimus Sodium in SLE
NCT00089804Phase 3Terminated
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Oct 2004
- Primary completion
- Feb 2009
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 30
01
Overview
A Phase 3 trial of abetimus sodium in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by La Jolla Pharmaceutical Company. Started Oct 2004; status: terminated.
02
Drugs
abetimus sodium
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00089804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089804.